Research Validates

 
News Articles for Research Validates top ^
Oracle OpenWorld – Canon Information and Imaging Solutions, Inc., a wholly owned subsidiary of Canon U.S.A., Inc., and a Gold level member of Oracle® PartnerNetwork (OPN), today announced that it has achieved Oracle Validated Integration of Enterprise Imaging Platform 1.2E with Oracle E-Business Suite 12.2. Enterprise Imaging Platform (EIP) is a single middleware platform that captures, creates, processes and automates document workflows while integrating relevant information into various enterprise applications.
Sign-up for Canon Information and Imaging Solutions, Inc. (CIIS) Achieves Oracle Validated Integration with Oracle E-Business Suite 12.2 investment picks
28-nm Runset Availability Enables Signoff Physical Verification for Mutual Customers MOUNTAIN VIEW, Calif.
Sign-up for SMIC Certifies Synopsys IC Validator for Signoff Physical Verification investment picks
Synopsys DRC and LVS Signoff Has Speed and Capacity to Handle Huge Flexible Screen Devices MOUNTAIN VIEW, Calif.
Sign-up for Synopsys' IC Validator Adopted by Plastic Logic for Physical Verification of Advanced Displays investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type.
Sign-up for European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer investment picks
Accreditation Now Inclusive of vCE's Advanced Non-Human Traffic Detection Practices RESTON, Va.
Sign-up for MRC Grants Continued Accreditation to comScore's vCE® Validation Service investment picks
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA ™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A.
Sign-up for Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review investment picks
Transgenomic, Inc. (NASDAQ:TBIO) , a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a research agreement with the University of Melbourne to conduct additional clinical validation studies of its Multiplexed ICE COLD-PCR TM (MX-ICP) technology.
Sign-up for Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE COLD-PCRTM to Enable Personalized Cancer Treatment investment picks
Rambus Inc. (NASDAQ:RMBS) and Mobiveil today announced they have validated interoperability of the Rambus R+™ DDR4 Multi-modal PHY with the Mobiveil Universal Multiport Memory Controller (UMMC) Core for JEDEC standard DDR4/3 and LPDDR3/2 operation.
Sign-up for Rambus and Mobiveil Partner to Bring Pre-Validated Solution to Chip Makers, Delivering Memory Flexibility and Accelerated Time-to-Market investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Medicines Agency (EMA) has validated and initiated its review of the company’s marketing authorization application (MAA) for Natpar ® (parathyroid hormone (rDNA)) for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH). If approved, Natpar would be the first and only PTH replacement therapy in Europe for patients with Hypoparathyroidism.
Sign-up for European Medicines Agency Validates Marketing Authorization Application for Natpar® (parathyroid hormone (rDNA)) in Hypoparathyroidism investment picks
Ixia (Nasdaq: XXIA) announced that Jaguar Network , a leading business internet service and cloud-hosting provider in France, has selected Ixia to ensure the company’s networks performed under growing usage and increasingly complex networking infrastructures.
Sign-up for Jaguar Network Selects Ixia to Help Validate Network Quality and Reliability investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) investment picks
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness Study, Including 20% African-American Men, Confirmed Similar Predictive Outcomes Regardless of Race REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients investment picks
http://media.marketwire.com/attachments/201003/3596_DigitalAlly.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1149038&ProfileId=051205&sourceType=1 LENEXA, KS --
Sign-up for United States Patent Office Questions Validity of Utility Associates' Boykin '556 Patent and Institutes Inter Partes Review investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1150803&ProfileId=051205&sourceType=1 ATLANTA, GA --
Sign-up for Fresh Promise Foods Announces Successful Validation of High Pressure Processed New Juices investment picks
To be Presented at SEG Conference in Denver WILMINGTON, Del.
Sign-up for US Seismic Systems, Inc. Technology Validated by Two Peer-Review Papers investment picks
2014/10/14
Garmin International Inc. and Jeppesen, a part of Boeing Commercial Aviation Services, today introduced the RNP AR NavData Service, a new tool for pilots utilizing Required Navigation Performance – Authorization Required (RNP AR) procedures.
Sign-up for Industry-First Automated RNP AR NavData Validation Service Introduced investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Validates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Universe  |  Next: Research Vice